Unlocking the Potential of Bronchoscopic Tumor Ablation: Safer, Faster, More Effective Treatments.
TumorBot™ Ablation System Transforms Lung Cancer Interventions with Breakthrough Technology.
Predictive Treatment Planning: Leveraging machine learning and cutting-edge image analytics, TumorBot predicts treatment outcomes and optimizes treatment planning, enhancing safety, efficacy, and efficiency. TumorBot can significantly reduce procedure times to less than one hour.
Self-Driving Transparenchyemal Robot: The TumorBot robot safely maneuvers through lung tissue to any nodule autonomously, optimizing device trajectory for comprehensive treatment. Experience unmatched safety and accuracy with TumorBot’s advanced autonomous navigation capabilities, including in the challenging peripheral regions of the lungs.
TumorBot™ aims to create new treatment paradigms for thoracic surgeons and interventional pulmonologists to address unmet needs of lung cancer patients. Using predictive treatment planning, self-driving robotics technology and flexible instrumentation, our mission is to fulfill the promise of bronchoscopic tumor ablation.
Rapid Growth in the Tumor Ablation Market
Tumor ablation is an increasingly important treatment option for lung cancer, and other cancers. This minimally invasive technique precisely targets cancerous tumors, preserving healthy tissue and minimizing recovery time. Ideal for smaller tumors (typically less than 3 cm), such as those found in early-stage cancers.
Tumor ablation is also an effective palliative procedure for managing recurrent or metastatic disease, enhancing quality of life when curative treatments are not viable. It is particularly suitable for patients who are unable to undergo surgery due to age or other health conditions, or who prefer a non-surgical approach.
The U.S. tumor ablation market is projected to grow significantly this decade, reaching an estimated USD $4.07 billion by 2030 with a compound annual growth rate (CAGR) of approximately 13.5%. This growth is driven by advancements in early cancer detection, such as liquid biopsies, and an aging population experiencing increasing cancer prevalence.
Enhance Your Lung Cancer Program with the TumorBot™ Ablation System
Treat More Patients: Treat more than twice as many patients with pinpoint access to peripheral and hard-to-reach areas of the lungs. Approximately 70% of lung nodules are found in the peripheral third of the lung.
Time Reduction: Halve procedure times with autonomous transparenchymal navigation and three-dimensional device maneuverability.
Enhanced Safety: Avoid critical anatomical structures, such as blood vessels and nerves, with autonomous transparenchymal navigation and flexible delivery needle.
Reach and Accuracy: Confidently access the entirety of the lungs with unparalleled accuracy.
Optimal Ablation Dosing: Use machine learning algorithms to tailor the ablation dose according to each device manufacturer’s specifications and tumor’s characteristics as well as your oncology team’s treatment goals.
Precision Planning: Calculate the ideal path and insertion angle and trajectory for the device based on patient-specific radiological and tumor data, ensuring comprehensive tumor ablation (+margin) to minimize recurrence.
Let’s advance localized cancer treatments together.
TumorBot’s Ablation System is not FDA cleared or approved, and is not available for sale in any country.